small molecule multikinase inhibitor sorafenib remains the only
molecularly targeted therapy approved by the FDA for the treatment of
hepatocellular carcinoma (HCC). Ongoing clinical trials are diligently
testing the potential for novel targeted agents or combination therapies
to further improve patient outcomes in this setting.
Sorafenib tosylate (Nexavar) was approved by the FDA in late 2007 for
the treatment of unresectable HCC, a decision based on the findings of
the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial.1According
to this multicenter, double-blind, phase III study, a randomized
protocol of either sorafenib or placebo in 602 advanced, untreated
patients with HCC, sorafenib led to statistically significant
improvement in overall survival compared with placebo.
- See more at: http://www.targetedonc.com/publications/hcc-monitor/2015/may-2015/Evolution-of-Treatment-for-HCC-Sorafenib-and-Beyond#sthash.OlPiai0z.dpuf
Labels: HCC, Nexavar, sorafenib, TACE, treatment for liver cancer